Baird Reiterates a 'Neutral' on AMAG Pharmaceuticals (AMAG); Worst Case Scenario Avoided, but Commercial HurdlesKeep Us Sidelined
Tweet Send to a Friend
Baird reiterates a 'Neutral' rating on AMAG Pharmaceuticals (NASDAQ: AMAG) and $20 price target.
Baird analyst says, "While a worst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst says, "While a worst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
